Tag: EMERALD-3
EMERALD-3 unlocks “secret key” to progression-free survival in locally advanced HCC
Single tremelimumab regular interval durvalumab (STRIDE) plus lenvatinib plus transarterial chemoembolization (TACE)—a standard treatment for embolization-eligible hepatocellular carcinoma (HCC) that induces tumour immune responses—has demonstrated...
